[go: up one dir, main page]

UA106636C2 - Морфолінотіазоли як позитивні алостеричні модулятори альфа 7 - Google Patents

Морфолінотіазоли як позитивні алостеричні модулятори альфа 7

Info

Publication number
UA106636C2
UA106636C2 UAA201205490A UAA201205490A UA106636C2 UA 106636 C2 UA106636 C2 UA 106636C2 UA A201205490 A UAA201205490 A UA A201205490A UA A201205490 A UAA201205490 A UA A201205490A UA 106636 C2 UA106636 C2 UA 106636C2
Authority
UA
Ukraine
Prior art keywords
morpholinotiazoles
positive allosteric
alpha modulators
modulators
alpha
Prior art date
Application number
UAA201205490A
Other languages
English (en)
Inventor
Грегор Джеймс Макдональд
Бек Бенойт Крістіан Альберт Гіслейн де
Джозеф Елизабет Лінаертс
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of UA106636C2 publication Critical patent/UA106636C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Даний винахід стосується похідних морфолінотіазолу і їх фармацевтично прийнятних солей, способів їх отримання, фармацевтичних композицій, що їх містять, і їх застосування в терапії.Винахід конкретно стосується позитивних алостеричних модуляторів нікотинових рецепторів ацетилхоліну, причому такі позитивні алостеричні модулятори мають здатність підвищувати ефективність агоністів нікотинових рецепторів.
UAA201205490A 2009-11-27 2010-11-25 Морфолінотіазоли як позитивні алостеричні модулятори альфа 7 UA106636C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09177347 2009-11-27
PCT/EP2010/068193 WO2011064288A1 (en) 2009-11-27 2010-11-25 Morpholinothiazoles as alpha 7 positive allosteric modulators

Publications (1)

Publication Number Publication Date
UA106636C2 true UA106636C2 (uk) 2014-09-25

Family

ID=42010343

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201205490A UA106636C2 (uk) 2009-11-27 2010-11-25 Морфолінотіазоли як позитивні алостеричні модулятори альфа 7

Country Status (25)

Country Link
US (1) US8637510B2 (uk)
EP (1) EP2504333B1 (uk)
JP (1) JP5636434B2 (uk)
KR (1) KR101749953B1 (uk)
CN (1) CN102639530B (uk)
AR (1) AR079205A1 (uk)
AU (1) AU2010323175B2 (uk)
BR (1) BR112012012657A2 (uk)
CA (1) CA2780218C (uk)
CL (1) CL2012001366A1 (uk)
CO (1) CO6531464A2 (uk)
DK (1) DK2504333T3 (uk)
EA (1) EA020275B1 (uk)
ES (1) ES2549917T3 (uk)
IL (1) IL219926A0 (uk)
JO (1) JO3078B1 (uk)
MX (1) MX349585B (uk)
MY (1) MY160728A (uk)
NZ (1) NZ600138A (uk)
PL (1) PL2504333T3 (uk)
SG (1) SG181054A1 (uk)
TW (1) TWI473803B (uk)
UA (1) UA106636C2 (uk)
WO (1) WO2011064288A1 (uk)
ZA (1) ZA201203856B (uk)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
JO2784B1 (en) * 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
EP2212309B1 (en) * 2007-10-18 2013-06-19 Janssen Pharmaceutica N.V. Trisubstituted 1,2,4-triazoles
CA2714662C (en) * 2008-03-19 2016-05-10 Janssen Pharmaceutica Nv Trisubstituted 1,2,4-triazoles as nicotinic acetylcholine receptor modulators
EA018187B1 (ru) * 2008-05-09 2013-06-28 Янссен Фармацевтика Нв Тризамещенные пиразолы в качестве модуляторов рецепторов ацетилхолина
KR101698250B1 (ko) 2010-05-17 2017-01-19 포럼 파마슈티칼즈 인크. (R)-7-클로로-N-(퀴누클리딘-3-일)벤조[b]티오펜-2-카르복사미드 히드로클로리드 모노히드레이트의 결정질 형태
GB201106829D0 (en) 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
CN103443092B (zh) 2011-02-03 2015-11-25 鲁平有限公司 用作α7胆碱受体调节剂的吡咯衍生物
HRP20161481T1 (hr) 2011-02-23 2016-12-30 Lupin Limited Derivati heteroarila kao modulatori nachr alfa7
MX344696B (es) 2011-03-31 2017-01-03 Lupin Ltd Derivados de pirrol como moduladores de los receptores de acetilcolina nicotinicos para su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer y la enfermedad de parkinson.
US8946432B2 (en) 2011-07-05 2015-02-03 Lupin Limited Biaryl derivatives as nAChR modulators
SG11201405239WA (en) * 2012-03-06 2014-09-26 Lupin Ltd Thiazole derivatives as alpha 7 nachr modulators
RU2635522C2 (ru) 2012-05-08 2017-11-13 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
WO2014072957A1 (en) 2012-11-12 2014-05-15 Lupin Limited Thiazole derivatives as alpha 7 nachr modulators
EP2945941B1 (en) 2013-01-16 2016-12-07 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
CN105051024A (zh) 2013-03-13 2015-11-11 鲁平有限公司 作为α7烟碱型乙酰胆碱受体的调节剂的吡咯衍生物
TW201446243A (zh) 2013-06-03 2014-12-16 Lupin Ltd 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑
AU2014282886A1 (en) 2013-06-17 2015-12-17 Lupin Limited Pyrrole derivatives as alpha 7 nAChR modulators
US11667638B2 (en) * 2016-08-19 2023-06-06 The University Of Bristol 4-substitued cytisine analogues
WO2020064655A1 (en) * 2018-09-24 2020-04-02 Astrazeneca Ab Azd0328 dosage regime for treating cognitive impairment
IL292388A (en) * 2019-10-21 2022-06-01 Cambridge Cognition Ltd Treatment of schizophrenic disorder using combined therapy
CN115317480B (zh) * 2022-09-01 2023-05-16 新乡医学院 N-(3-甲基-5-异噻唑基)-2-氧代-3-(2h)-苯并噁唑乙酰胺的药物应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1381603A2 (en) * 2000-08-18 2004-01-21 PHARMACIA & UPJOHN COMPANY Quinuclidine-substituedaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
WO2004091480A2 (en) 2003-04-09 2004-10-28 Exelixis, Inc. Tie-2 modulators and methods of use
EP1884513A4 (en) 2005-05-23 2010-04-28 Japan Tobacco Inc PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME
EA015034B1 (ru) * 2005-09-13 2011-04-29 Янссен Фармацевтика Н.В. 2-анилин-4-арилзамещенные тиазольные производные
CN101374810A (zh) * 2006-01-18 2009-02-25 锡耶纳生物技术股份公司 α7烟碱型乙酰胆碱受体的调节剂及其治疗用途
JO3019B1 (ar) * 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv ثلاثي مستبدل 4،2،1-ثلاثي زولات
BRPI0910585A2 (pt) 2008-04-17 2015-09-22 Glaxo Group Ltd indóis como moduladores de receptor de aceticolina nicotínica do subtipo alfa-7
AU2014315050A1 (en) 2013-09-09 2016-03-24 Melinta Therapeutics, Inc. Antimicrobial compunds and methods of making and using the same

Also Published As

Publication number Publication date
JO3078B1 (ar) 2017-03-15
ES2549917T3 (es) 2015-11-03
EA201290394A1 (ru) 2012-10-30
BR112012012657A2 (pt) 2016-07-12
TWI473803B (zh) 2015-02-21
CN102639530B (zh) 2014-08-06
EP2504333B1 (en) 2015-07-15
CO6531464A2 (es) 2012-09-28
EP2504333A1 (en) 2012-10-03
ZA201203856B (en) 2015-01-28
MX349585B (es) 2017-08-03
AR079205A1 (es) 2012-01-04
KR20120102083A (ko) 2012-09-17
AU2010323175B2 (en) 2014-06-26
MY160728A (en) 2017-03-15
US8637510B2 (en) 2014-01-28
PL2504333T3 (pl) 2015-12-31
AU2010323175A1 (en) 2012-05-10
CL2012001366A1 (es) 2012-10-05
NZ600138A (en) 2013-05-31
CN102639530A (zh) 2012-08-15
US20120238561A1 (en) 2012-09-20
HK1171449A1 (en) 2013-03-28
MX2012006082A (es) 2012-06-19
CA2780218C (en) 2018-10-16
SG181054A1 (en) 2012-07-30
TW201127836A (en) 2011-08-16
JP5636434B2 (ja) 2014-12-03
IL219926A0 (en) 2012-07-31
EA020275B1 (ru) 2014-09-30
DK2504333T3 (en) 2015-10-19
WO2011064288A1 (en) 2011-06-03
CA2780218A1 (en) 2011-06-03
KR101749953B1 (ko) 2017-06-22
JP2013512218A (ja) 2013-04-11

Similar Documents

Publication Publication Date Title
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
MY149731A (en) Compounds
MX2011008634A (es) Derivados de aminotetralina composiciones farmaceuticas que los contienen y su uso en terapia.
UA109010C2 (en) Morpholino pyrividines and their use in therapy
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
EA201200618A1 (ru) Производные хроменона с антиопухолевой активностью
EA201071288A1 (ru) Тризамещенные пиразолы в качестве модуляторов рецепторов ацетилхолина
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
MX388963B (es) Formulacion farmaceutica acuosa de tapentadol para administracion oral
MX338515B (es) Derivados de tetrahidroquinolina utiles como inhibidores de bromodominio.
ECSP14013217A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk.
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
IN2014MN02598A (uk)
MX2013001677A (es) Formulaciones estables de linaclotida.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
MX2014006004A (es) Derivados de aminobenzociclohepteno, aminotetralina, aminoindano y fenalcilamina n-sustituidas, composiciones farmaceuticas que los contienen, y su uso en terapia.
MX2015011614A (es) Derivados de pirrolidina, composiciones farmaceuticas que los contienen, y su uso en terapia.
UA109803C2 (xx) (ПІРИДИН-4-ІЛ)БЕНЗИЛАМІДИ ЯК АЛОСТЕРИЧНІ МОДУЛЯТОРИ АЛЬФА-7 nAChR
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
EA201490573A1 (ru) Соединение бензотиазолона
BR112013025610A2 (pt) uso de um metapneumovírus aviário vivo, e, composição farmacêutica
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина